Zyversa Therapeutics Inc
ZVSA0.311USD
-0.238-43.30%
收盤 08/04, 16:00（美東）報價延遲15分鐘
799.48K總市值
虧損本益比TTM
關於 Zyversa Therapeutics Inc 公司
ZyVersa Therapeutics, Inc. 是一家臨牀階段專業生物製藥公司。該公司專注於利用先進技術爲患有慢性腎臟或炎症疾病的患者開發藥物。其領先的腎臟候選藥物膽固醇流出介質 VAR 200（2-羥丙基-β-環糊精或 2HBCD）正在開發中，用於治療多種腎臟疾病。其領先的抗炎候選藥物炎症小體 ASC 抑制劑 IC 100 是一種人源化單克隆抗體，正在開發中，用於治療多種炎症疾病。其腎臟管線最初專注於罕見的慢性腎小球疾病。VAR 200 的主要適應症是局竈節段性腎小球硬化症 (FSGS)。VAR 200 的活性成分 2HBCD 由七個糖分子組成，它們結合在一起形成一個 3-D 環，具有疏水核心和親水外部。 VAR 200 通過與腎小球膜的親水成分相互作用，被動和主動介導膽固醇外流。
公司簡介
公司代碼ZVSA
公司名稱Zyversa Therapeutics Inc
上市日期Dec 21, 2021
CEOMr. Stephen C. (Steve) Glover
員工數量7
證券類型Ordinary Share
年結日Dec 21
公司地址2200 N. Commerce Parkway
城市WESTON
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編33326
電話17542311688
網址https://www.zyversa.com/
公司代碼ZVSA
上市日期Dec 21, 2021
CEOMr. Stephen C. (Steve) Glover
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
1.82K
--
Mr. Peter Wolfe
Mr. Peter Wolfe
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
127.00
--
Mr. Pablo A. Guzman, M.D.
Mr. Pablo A. Guzman, M.D.
Chief Medical Officer, Senior Vice President - Medical Affairs
Chief Medical Officer, Senior Vice President - Medical Affairs
76.00
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
--
--
Dr. Min Chul Park, Ph.D.
Dr. Min Chul Park, Ph.D.
Independent Director
Independent Director
--
--
Mr. James E. Sapirstein
Mr. James E. Sapirstein
Independent Director
Independent Director
--
--
Ms. Karen A. Cashmere
Ms. Karen A. Cashmere
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Robert G. (Rob) Finizio
Mr. Robert G. (Rob) Finizio
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
1.82K
--
Mr. Peter Wolfe
Mr. Peter Wolfe
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
127.00
--
Mr. Pablo A. Guzman, M.D.
Mr. Pablo A. Guzman, M.D.
Chief Medical Officer, Senior Vice President - Medical Affairs
Chief Medical Officer, Senior Vice President - Medical Affairs
76.00
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
--
--
Dr. Min Chul Park, Ph.D.
Dr. Min Chul Park, Ph.D.
Independent Director
Independent Director
--
--
Mr. James E. Sapirstein
Mr. James E. Sapirstein
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月28日 週三
更新時間: 5月28日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Armistice Capital LLC
5.85%
UBS Financial Services, Inc.
0.58%
Geode Capital Management, L.L.C.
0.45%
Virtu Americas LLC
0.36%
INCON Co., Ltd.
0.09%
Other
92.68%
持股股東
持股股東
佔比
Armistice Capital LLC
5.85%
UBS Financial Services, Inc.
0.58%
Geode Capital Management, L.L.C.
0.45%
Virtu Americas LLC
0.36%
INCON Co., Ltd.
0.09%
Other
92.68%
股東類型
持股股東
佔比
Hedge Fund
5.89%
Investment Advisor
0.58%
Investment Advisor/Hedge Fund
0.45%
Research Firm
0.36%
Corporation
0.09%
Individual Investor
0.04%
Other
92.59%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
35
361.22K
7.41%
+216.61K
2025Q1
36
361.22K
7.45%
+216.32K
2024Q4
37
136.78K
7.85%
+71.47K
2024Q3
62
57.46K
5.12%
-24.65K
2024Q2
59
16.60K
1.67%
-51.32K
2024Q1
59
17.73K
1.94%
-42.02K
2023Q4
64
48.48K
46.23%
+4.78K
2023Q3
64
46.91K
75.21%
+1.88K
2023Q2
61
49.59K
86.96%
+14.63K
2023Q1
50
16.17K
61.42%
-21.60K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Armistice Capital LLC
285.04K
5.85%
+285.04K
--
Mar 31, 2025
UBS Financial Services, Inc.
28.33K
0.58%
+24.14K
+576.55%
Mar 31, 2025
Geode Capital Management, L.L.C.
21.71K
0.45%
+13.81K
+175.00%
Mar 31, 2025
Virtu Americas LLC
17.53K
0.36%
-7.73K
-30.61%
Mar 31, 2025
INCON Co., Ltd.
4.28K
0.09%
--
--
Dec 31, 2023
Tower Research Capital LLC
2.15K
0.04%
-1.33K
-38.13%
Mar 31, 2025
Glover (Stephen C)
1.82K
0.04%
--
--
Apr 15, 2025
Wolfe (Peter)
127.00
0%
--
--
Apr 15, 2025
BofA Global Research (US)
111.00
0%
+2.00
+1.83%
Mar 31, 2025
Guzman (Pablo A)
76.00
0%
--
--
Apr 15, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Mar 08, 2024
Merger
10<1
Mar 08, 2024
Merger
10<1
Mar 08, 2024
Merger
10<1
Mar 08, 2024
Merger
10<1
Nov 30, 2023
Merger
35<1
Nov 30, 2023
Merger
35<1
公告日期
類型
比率
Mar 08, 2024
Merger
10<1
Mar 08, 2024
Merger
10<1
Mar 08, 2024
Merger
10<1
Mar 08, 2024
Merger
10<1
Nov 30, 2023
Merger
35<1
Nov 30, 2023
Merger
35<1
Nov 30, 2023
Merger
35<1
Nov 30, 2023
Merger
35<1
